



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/486,266	05/03/2000	THOMAS HILLE	FLA-0035	3529

7590 11/14/2002

D. Peter Hochberg Co LPA  
1940 E. 6th Street - 6th Floor  
Cleveland, OH 44114-2294

EXAMINER
----------

GHALI, ISIS A D

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED: 11/14/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/486,266	HILLE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Isis Ghali	1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1) Responsive to communication(s) filed on 29 August 2002.

2a) This action is **FINAL**.                            2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4) Claim(s) 22-33,35-39,41-49,53-55 and 57-68 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 22-33, 35-39, 41-49, 53-55, 57-68 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 19.

4) Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_.

5) Notice of Informal Patent Application (PTO-152)

6) Other: \_\_\_\_\_.

## **DETAILED ACTION**

The receipt is acknowledged of applicants' request under 1.114, preliminary amendment D, and request for extension of time, all filed 08/29/2002; and IDS, filed 9/23/2002.

Claims 22-33, 35-39, 41-49, 53-55, 57-68 are pending in the application.

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/29/2002 has been entered.

### ***Specification***

2. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

***Claim Rejections - 35 USC § 103***

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

5. Claims 22-33, 35-39, 41-49, 53-55, and 57-66 are rejected under 35 U.S.C. 103(a) as being unpatentable over any of US 4,390,520 ('520) (DE 1667 944 ('944) or US 5,225,199 ('199) each by itself or US '520 or DE '944 in combination with US '199.

US '520 discloses a transdermal analgesic adhesive comprising a pressure sensitive adhesive layer containing the drug and a flexible substrate (backing). The backing expands on one direction and prepared from polyethylene and having a

moisture permeability from 5 to 2000 g/m<sup>2</sup>/hr. The adhesive layer comprises vinyl pyrrolidone (abstract; col.2, lines 49-68; col.3, lines 1-2, 55-56).

DE '944 teaches plaster bandage comprising a woven fabric base, which is elastically stretchable in a transverse or longitudinal direction (English translation of the claim).

US '199 teaches a pharmaceutical plaster comprising film layer (represents the backing), adhesive layer containing the drug such as hormone or buprenorphine, and another covering layer removed before use. The film layer has elongation (elasticity) of 30 to 150 % and made of polyethylene terephthalate (abstract; col.3, lines 58-61; col.5, lines 34-35).

No superior and unexpected results were established showing the criticality of the claimed ranges of wrap thread and weft thread. It is within the skill in the art to have differentiated marking elements.

Accordingly, it would have been obvious to one having ordinary skill in the art at the time of the invention to deliver transdermal therapeutic system comprising adhesive reservoir layer containing the active ingredient; a release liner; and a uni-directional elastic backing disclosed by US '520 or DE '944 and adjusting the elasticity of the backing to that percentage disclosed by US '199, motivated by the teaching of US '520 and US '199 that the elasticity of the backing prevents the sense of tension from the skin, with reasonable expectation of success of delivering a comfortable patch.

***Response to Arguments***

6. Applicant's arguments filed 08/29/2002 have been fully considered but they are not persuasive.

**Applicants argue that:**

- US '199 teaches a plaster comprising film layer with an elongation of 30 to 150% in two directions and an additional backing sheet laminated through adhesive to the film layer, thus, the backing layer and the film layer are two singular, individual and distinct layers. No disclosure in US '199 that the backing layer being unidirectional elastic material having elasticity of at least 20%.
- Regarding US '520, applicants admit that he reference teaches flexible and elastic backing, but argue that the wording "expanding in at least one direction" is not clear and ambiguous description of a unidirectional elastic material having elasticity of at least 20%.
- The teachings of US '199 and US '520 separately or in combination address a problem different from the present invention which is being pleasant for use during long time and minimizing curling effect during manufacture.

**In response to the above argument, the examiner position is:**

- US '199 teaches the film layer that stay on patient skin, along with the drug-containing layer, i.e. the film layer is actually the backing layer and performs the

function and made from the same material as applicant's backing layer, but it is named differently. The film layer represents the backing layer. The backing sheet of the reference is a protective layer that is used for leaving the film layer and the drug-containing adhesive on the human skin by applying the plaster and then removing the sheet therefrom (col.7, lines 54-56). Some embodiments of the references do not even have the backing layer, only the film layer (figure 2 and example 4). The elasticity claimed by the applicants is more than 20%, and the reference disclosed from 30-150%, i.e. that reference meets the claimed ratio. It is within the skill in the art to determine the unidirectional elasticity depending on the required stretchability of the backing layer or motivated by the teaching of US '520 that the backing can have only elasticity in one direction. Note that the "comprising" claims language permits the presence of other layers.

- US '520 clearly teaches that the backing layer expands only in one direction and determining the ratio of the elasticity is within the skill in the art or is taught by US '199 to be between 30-150%.
- The examiner recognizes that obviousness can only be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See *In re Fine*, 837 F.2d 1071, 5 USPQ2d 1596 (Fed. Cir. 1988) and *In re Jones*, 958 F.2d 347, 21 USPQ2d 1941 (Fed. Cir. 1992). In this case, US '199 suggests the amount of elasticity and US '520 suggests the

unidirectional elasticity. Thus, it would have been obvious to one having ordinary skill in the art at the time of the invention to deliver a transdermal therapeutic system comprising a unidirectional elastic backing as disclosed by US '520 and adjusting the elasticity of the backing to that percentage disclosed by US '199, motivated by the teaching of US '520 and US '199 that the elasticity of the backing prevents the sense of tension from the skin, with reasonable expectation of success of delivering a comfortable patch. In response to applicant's argument that the references address problems different from the present invention, the fact that applicant has recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious. See *Ex parte Obiaya*, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985). In any event, the references teach the properties desired by applicants. US '199 teaches that the film layer having an elasticity from 30-150% provides no breakage and no peeling from the skin because of its satisfactory stretchability that is enough to follow skin contraction and expansion (col.2, lines 25-28). The reference, furthermore, discloses that the elasticity between 30-150% provides the best handability and less damage to the plaster on application (col.4, lines 44-48). US '520 teaches that the elastic backing follows the expansion and contraction of the skin when applied to the body (col.3, lines 4-6). Therefore, the cited references provide the features desired by applicants, which are comfortability and less curling during manipulation.

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Isis Ghali whose telephone number is (703) 305-4048. The examiner can normally be reached on Monday through Thursday from 7:00 AM to 5:30 PM, Eastern Time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page, can be reached on (703) 308-2927. The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3592.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 305-1235.

Isis Ghali  
Examiner  
Art Unit 1615

THURMAN K. PAGE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

